$MOH (Molina Healthcare, Inc.)

$MOH {{ '2016-04-20T04:21:27+0000' | timeago}} • Announcement

$MOH said it will fund the Total Care plan purchase with available cash. Total Care is a prepaid health services plan that provides health care coverage to about 39,000 members under the Medicaid and Child Health Plus programs in 3 upstate New York counties. The deal is expected to close in 3Q16.

$LLY {{ '2017-07-25T15:33:57+0000' | timeago}} • Announcement

$LLY and its development and marketing partner $INCY announced that resubmission of rheumatoid arthritis drug baricitinib will be delayed beyond 2017 and at least it will take 18 months. FDA has demanded for a new trial. ELi Lilly added that baricitinib tablets have been approved since Feb 2017 in EU and the drug was approved recently in Japan.

$BIIB {{ '2017-07-25T15:15:33+0000' | timeago}} • Announcement

$BIIB named Alisha Alaimo as SVP of US Therapeutic Operations. In this position, Alaimo will lead $BIIB's sales and marketing, market access, patient services and commercial operations and strategy. Alaimo will join the company from $NVS, where she was VP and Head of its Cardiovascular Business Unit.

$BIIB {{ '2017-07-25T15:07:04+0000' | timeago}} • Announcement

On a segment basis, $BIIB's revenue for TECFIDERA, PLEGRIDY and FAMPYRA increased YoY in 2Q17, while total Total Interferon and AVONEX reported decline in revenues. In other products, Biosimilars revenue surged significantly to $91MM in the quarter from $15MM a year ago.

$BMY {{ '2017-07-25T15:05:20+0000' | timeago}} • Announcement

The FDA has accepted $BMY's supplemental Biologics License Applications to update Opdivo dosing to include 480 mg infused over 30 minutes every four weeks for all currently approved monotherapy indications. The applications are under review with an action date of March 5, 2018. Opdivo has become important treatment option across multiple cancers.

$BIIB {{ '2017-07-25T14:59:43+0000' | timeago}} • Announcement

The drug maker $BIIB increased its revenue outlook for FY17 to $11.5-11.8Bil, due to faster than expected adoption of SPINRAZA in the US. GAAP diluted EPS guidance was narrowed to $17.05-17.65 from the earlier guidance of $18-18.80. Adjusted EPS guidance, however, was raised to $2.80-21.40 from the prior guidance of $20.45-21.25.

$BIIB {{ '2017-07-25T14:47:25+0000' | timeago}} • Announcement

$BIIB, which competes with $ABT and $PFE, posted record 2Q17 revenue, on strong Spinraza demand in the US, though YoY profit fell 18% on higher expenses. Net earnings attributable to Biogen plunged to $862.8MM, while diluted EPS fell 15.03% to $4.07. Revenue, however, jumped 6% to $3.1Bil. $BIIB lifted its outlook due to strong Spinraza sales.

$BIIB {{ '2017-07-25T12:18:23+0000' | timeago}} • Announcement

$BIIB Biogen Inc. Earnings AlphaGraphic: Q2 2017 Highlights

$JNJ {{ '2017-07-24T17:21:48+0000' | timeago}} • Announcement

$JNJ said preliminary data from a phase 1/2a clinical trial on an investigational HIV-1 vaccine regimen showed positive results in a sample of 393 healthy volunteers. If the vaccine clears the phase 3 trials, its launch can be expected within a decade. There are currently around 37MM AIDS patients around the world.

$BMY {{ '2017-07-24T16:32:02+0000' | timeago}} • Announcement

$BMY said the U.S. Food and Drug Administration (FDA) has expanded the indication for Yervoy (ipilimumab) injection for intravenous use to now include the treatment of unresectable or metastatic melanoma in pediatric patients 12 years of age and older.

$ABBV {{ '2017-07-21T16:09:32+0000' | timeago}} • Announcement

$ABBV received positive opinion from the European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency for Humira (adalimumab) for the treatment of chronic non-infectious anterior uveitis in pediatric patients. Uveitis is an inflammation of the uvea, which includes the iris, choroid, and the ciliary body in eye.

$ENDP {{ '2017-07-21T14:56:21+0000' | timeago}} • Announcement

$ENDP said it will be ceasing operations and closing its manufacturing and distribution facilities in Huntsville, Alabama. The closure is expected to take place over the next 12 to 18 months. These restructuring actions are expected to reduce $ENDP's workforce by about 875 positions and to result in pre-tax restructuring charges of about $325MM.

$INCY {{ '2017-07-20T13:24:37+0000' | timeago}} • Announcement

$INCY said first patient has been treated in Phase 3 trial of itacitinib for the first-line treatment of patients with acute graft-versus-host disease (GVHD). GVHD is a condition that might occur after an allogeneic transplant, whereby the donated bone marrow or peripheral blood stem cells view the recipient’s body as foreign and attack the body.

$UNH {{ '2017-07-18T21:56:14+0000' | timeago}} • Webcast

In Optum segment, $UNH is focusing on three key areas for growth; strong sales pipeline of $40Bil, growing YTD sales and backlog. On MedicareAdvantage, the company expects to outperform the market in 2018 with a positive long-term outlook for the industry. $UNH also feels that the return of insurer's fee will be the single largest headwind in 2018.

$UNH {{ '2017-07-18T21:51:39+0000' | timeago}} • Webcast

Despite forgoing over $1.8Bil in revenues due to the withdrawal from the ACA individual insurance market and the health insurance tax moratorium, $UNH revenues increased nearly 9% to $40.8Bil. Health insurer also announced that the partnership with AARP will continue through at least 2025 to offer Medicare related products under AARP brand.

$UNH {{ '2017-07-18T21:48:14+0000' | timeago}} • Webcast

Health insurance giant $UNH said it served 2.5MM more people in 2Q17 vs. 2Q16, excluding the individual market. The business model of the insurer is focused on addressing the healthcare needs of consumers in areas like group Medicare Advantage, Medicaid programs in emerging markets like Brazil and established markets.

$UNH {{ '2017-07-18T21:45:28+0000' | timeago}} • Webcast

$UNH expects its stellar performance in first half to carry forward in the second half of 2017 and into 2018. On a global basis, the insurer serves 139MM people, including 126MM in the United States. UnitedHealth believes it is on target to exceed the $200Bil mark in 2017 for the first time.

$JNJ {{ '2017-07-18T19:50:54+0000' | timeago}} • Webcast

$JNJ expects that the growth acceleration in the back half of 2017 will create some momentum going into 2018, as the majority of growth acceleration in both Hospital Medical Devices and Consumer have to do with new product launches. However, the company said it is not prepared to talk about guidance.

$JNJ {{ '2017-07-18T19:30:46+0000' | timeago}} • Webcast

$JNJ CEO Alex Gorsky said during the conference call, "We remain very optimistic about Pharma in the second half of the year and we continue to see really strong uptake both with DARZALEX and the various multiple myeloma indications earlier utilization."

$JNJ {{ '2017-07-18T18:58:31+0000' | timeago}} • Webcast

$JNJ said it has a pipeline of more than 10 new blockbuster products to launch or file for regulatory approval in the next five years, each with greater than $1Bil in peak year sales potential.

$UNH {{ '2017-07-18T14:47:02+0000' | timeago}} • Announcement

$UNH's 2Q revenues increased approx. 8% crossing $50Bil. The insurer is on target to reach annual revenues of $200Bil for the first time. Total enrollment jumped 3% to 49.5MM people. Medical care ratio (MCR), a key indicator to measure financial health of insurance firms, increased 20 bps reaching 82.2%, in line with industry standards.

Recent Transcripts

UNH (UnitedHealth Group Incorporated)
Tuesday, July 18 2017 - 12:45pm
JNJ (Johnson & Johnson)
Tuesday, July 18 2017 - 12:30pm
ENZ (Enzo Biochem Inc.)
Friday, June 9 2017 - 12:30pm
DXC (DXC Technology Company)
Thursday, May 25 2017 - 9:00pm
ACAD (ACADIA Pharmaceuticals Inc.)
Tuesday, May 9 2017 - 9:00pm
GTS (Triple-S Management Corporation)
Tuesday, May 9 2017 - 1:00pm
ENDP (Endo International plc)
Tuesday, May 9 2017 - 12:30pm
VRX (Valeant Pharmaceuticals International, Inc.)
Tuesday, May 9 2017 - 12:00pm
CI (Cigna Corp.)
Friday, May 5 2017 - 12:30pm
MOH (Molina Healthcare, Inc.)
Thursday, May 4 2017 - 9:00pm
BMRN (BioMarin Pharmaceutical Inc.)
Thursday, May 4 2017 - 8:30pm
INCY (Incyte Corporation)
Thursday, May 4 2017 - 2:00pm
HUM (Humana Inc.)
Wednesday, May 3 2017 - 1:00pm
OMI (Owens & Minor Inc.)
Wednesday, May 3 2017 - 12:30pm
WCG (WellCare Health Plans, Inc.)
Wednesday, May 3 2017 - 12:00pm
AET (Aetna Inc.)
Tuesday, May 2 2017 - 12:30pm
BMY (Bristol-Myers Squibb Company)
Thursday, April 27 2017 - 2:30pm
ABBV (AbbVie Inc.)
Thursday, April 27 2017 - 1:00pm
MGLN (Magellan Health, Inc.)
Wednesday, April 26 2017 - 2:00pm
ANTM (Anthem, Inc.)
Wednesday, April 26 2017 - 12:30pm

AlphaGraphics you may like